Developing Novel Therapeutics Targeting oxMIF in Cancer & Autoimmune Diseases
Combating solid tumors and chronic inflammation by targeting oxMIF with novel therapeutic antibodies. OncoOne discovered the key to targeting the macrophage migration inhibitory factor (MIF).
oxMIF: we discovered it, we named it, we are drugging it
OncoOne is dedicated to developing novel therapeutics for patients living with solid tumors and autoimmune diseases. Our founders discovered the disease-related and druggable isoform of one of the most important drivers of innate and adaptive immunity: the macrophage migration inhibitory factor (MIF). The founders identified and named this new target the oxidized macrophage migration inhibitory factor or oxMIF.
MIF, a critical yet previously elusive target
Over 3,000 peer-reviewed papers detail MIF’s importance in driving tumor progression and metastases as well as inflammation. MIF is a central mediator of both innate and adaptive immunity in cancer and immunology indications that has remained elusive to drug targeting.
oxMIF, overcoming previous limitations of targeting MIF
MIF aggregates and goes through a confirmational change to oxMIF at sites of inflammation and in malignant tissue. OncoOne’s therapies specifically target oxMIF, which is only found at the site of disease.
Our therapeutic focus: Immunotherapy for Cancer & Autoimmune Diseases
We are developing oxMIF-targeting therapies for oncology and immunology indications. OncoOne’s initial focus is on treating solid tumors while we advance our second anti-oxMIF mAb to treat patients with chronic inflammatory diseases. All indications in our focus represent significant unmet medical needs.
experienced
flexible
innovative
responsive
collaborative
OncoOne Newsletter
“OncoOne has had a successful start to 2023, with the lead oxMIF mAb for solid tumors, ON203, being featured in the American Association for Cancer Research’s journal Molecular Cancer Therapeutics……
I could not be prouder of my team of experts at OncoOne — we hope to see you all in the months ahead!“
Message from the CEO, Dr. Randolf Kerschbaumer
Recent Publications
Rossmueller G. & Mirkina I. et al., “Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic”, Molecular Cancer Therapeutics 2023, 22:1–15
Targeting oxMIF in Cancer and Chronic Inflammation
oxMIF in Oncology
We are developing an improved, second generation anti-oxMIF antibody, ON203 for the treatment of patients living with solid tumors. ON203 is being designed for application both as a monotherapy and in combination with standard-of-care regimens in tumor indications with high unmet medical need.